Acute Coronary Syndromes

Company announces reinitiation of phase IIa trial in ACS

Published in Blood Weekly, June 10th, 2004

Nuvelo, Inc., (NUVO) announced reinitiation and enrollment of the first patient in a phase IIa trial with recombinant nematode anticoagulant protein c2 (rNAPc2), for the treatment of patients with acute coronary syndromes (ACS).

After licensing the molecule from Dendreon Corp. in February 2004, Nuvelo took steps to reinitiate the study also referred to as ANTHEM (Anticoagulation with NAPc2 To Help Eliminate Mace)/TIMI 32. Prior to reinitiation, 77 patients had been enrolled in the trial. An additional 98 patients will be enrolled in this phase of the trial for a total of 175 patients in centers across the United States and Canada.

The multicenter,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2004-06-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry